PSTV Cytori Therapeutics: Enterprise Value-to-Revenue Ratio

Official company branding of Plus Therapeutics, Inc. (PSTV)

Risks for Plus Therapeutics, Inc. (PSTV) are linked to the potential failure of its radiopharmaceutical platform and R&D expenditures, which is reflected in the EV/Sales trend, where the current mark equals 2364.86. Plus Therapeutics, Inc. (PSTV) is implementing software robots for clinical data analysis and automating molecule screening. High margins are sustained through a network of specialized hubs for the ultra-fast delivery of isotopes.

PSTV Plus Therapeutics Inc Enterprise Value-to-Revenue Ratio (11/23/2025 - 08/03/2026)

Financial and market metric breakdowns for Cytori Therapeutics (PSTV)

- stock quotes and analyst forecast:
Fundamental company valuation:Plus Therapeutics Inc PSTV
Product sample of Plus Therapeutics Inc

This indicator determines the total enterprise value minus net debt per unit of annual revenue, allowing for the assessment of future synergies and the avoidance of overpaying for an asset. By analyzing the EV/Revenue multiple, an investor can see how the market values the unique targeted radiotherapy ecosystem of Plus Therapeutics, Inc. (PSTV), which integrates pharmaceuticals with navigation systems for the unrivaled treatment of brain tumors.